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ABSTRACT
Introduction: Uveitis specialists and
rheumatologists treat patients with anterior
scleritis, but data from controlled trials to
guide management are scarce, making
differences in treatment paradigms possible.
Methods: 1044 uveitis specialists and
rheumatologists were surveyed regarding
therapy for a patient with anterior scleritis.
Respondents were asked to select first- and
second-choice therapies and then reselect
therapies assuming that the costs of all
options were equal and that insurance
approval was ensured. Fisher’s exact tests were
employed to compare selections.
Results: Ninety-two respondents (8.6%)
completed the survey. Methotrexate was the
most-selected first-choice treatment before
equalization of cost/insurance factors among
uveitis specialists (44.4%) and rheumatologists
(78.6%) (p\0.009). Uveitis specialists selected
mycophenolate at a higher rate (27.8%) than
did rheumatologists (5.3%) (p\0.015). Cost
and insurance considerations were not
significant.
Conclusions: Uveitis specialists and
rheumatologists have different preferences in
the treatment of anterior scleritis. The
difference is impacted more by specialty
practice than by cost/insurance.
Keywords: Cost; Insurance; Scleritis; Specialty;
Uveitis
INTRODUCTION
Anterior scleritis accounts for 99% of cases of
scleritis, the vast majority of which are due to a
noninfectious etiology. The incidence of
scleritis is approximately 3.4 per 100,000
person-years [1]. Scleritis is associated with a
systemic inflammatory disease in 30–40% of
patients [1, 2]. In these patients, the treatment
of ocular inflammation is partially dictated by
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treatment choices for the underlying systemic
illness [3]. In patients without an underlying
systemic illness, there is no clear consensus on
optimal treatment regimen, and there are a
wide array of potential therapeutic options
[3–8].
Randomized controlled trials (RCTs) provide
the highest level of evidence for treatment
efficacy in the pharmacologic management of
disease; however, scleritis has not been studied
in this manner. There are several reasons for the
lack of RCT data on this disease, including the
cost considerations of carrying out such a trial
and problems related to patient recruitment for
a disease with low prevalence.
Formal treatment recommendations and
guidelines are often derived from data from
RCTs as well as meta-analyses; in their absence,
recommendations are often formed by
consensus of expert opinion. We have
previously shown that subspecialists differ
significantly in their recommendations for the
management of intermediate and posterior
uveitis [9–11]. These differences are influenced
by subspecialty training as well as issues
concerning cost and prior authorization by
insurance companies. We sought to examine
the treatment preferences of uveitis specialists
and rheumatologists in the management of
idiopathic scleritis, with the specific aim of
identifying factors which influence treatment
choice.
METHODS
We constructed an email questionnaire that
included a brief case vignette describing a
patient with idiopathic scleritis involving one
eye. Exempt status was obtained from the
Colorado Multiple Institutional Review Board;
all data were collected voluntarily and
anonymously. The survey was developed using
Survey Monkey, and responses were collected
through this online tool as well. Respondents to
the survey were asked whether they were
members of the American Uveitis Society, the
American College of Rheumatology, or neither.
Survey respondents were then presented with a
clinical case vignette: ‘‘A 40 year old male has
non-necrotizing painful nodular scleritis in the
right eye. He has no systemic symptoms and
laboratory work-up is negative. His scleritis has
not been controlled with systemic NSAIDs and is
still active on 20 mg prednisone daily. He has
been referred to rheumatology for consideration
of systemic immunosuppression.’’ Survey
respondents were asked whether they would
personally manage the patient or refer him to
another specialist. Those who elected to manage
the patient were asked to select first- and
second-choice treatment options. The reason
for needing to choose a second-choice option
was not defined by the survey. They were then
asked again for first and second treatment
choices assuming that the cost to the patient
was the same for any medication chosen and
there would be no issues with prior
authorization from the patient’s insurance
provider (cost/authorization equalized). Possible
treatment choices were dexamethasone implant,
fluocinolone acetonide implant, methotrexate,
cyclosporine, mycophenolate mofetil,
infliximab, adalimumab, rituximab, and ‘‘other’’
(a free text response that allowed respondents to
enter additional treatment options not already
specified). Periocular triamcinolone injections
and azathioprine were frequent responses in
this category and so were included in the
analysis in their appropriate categories.
The survey was sent via email to members of
the American Uveitis Society discussion group
and to members of the American College of
Rheumatology. Because the American College
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of Rheumatology is a much larger group,
one-sixth of its members were randomly
selected. Respondents to the survey from the
American Uveitis Society discussion group were
categorized as uveitis specialists. Those who
responded from the American College of
Rheumatology were categorized as
rheumatologists. The Survey Monkey tool
allowed the survey to be completed only once
per computer, preventing multiple responses
from a single recipient.
To analyze the effect of cost and prior
authorization, treatment options were grouped
into (1) local steroid injections (dexamethasone
implant, fluocinolone acetonide implant, and
periocular triamcinolone injection); (2)
nonbiologic immunosuppressive medications,
also known as disease-modifying antirheumatic
drugs (DMARDs: methotrexate, azathioprine,
cyclosporine, and mycophenolate mofetil); (3)
biologic immunosuppressive agents (infliximab,
adalimumab, etanercept, and rituximab).
Two-by-two contingency tables were used to
compare the distribution of treatment choices
before and after equalization of cost/
authorization. For each specialty, first choices
were compared before and after cost and prior
authorization were equalized, and then second
choices were compared in the same manner
using Fisher’s exact test. Significant p values
were adjusted for false discovery rate/multiple
comparisons where appropriate.
RESULTS
A total of 92 out of 1044 physicians completed
the survey and were willing to recommend
treatment for the scleritis case vignette
(response rate 8.6%). Thirty-six of the 192
email recipients (18.8%) responded from the
American Uveitis Society discussion group,
while 56 of 852 rheumatologists (6.3%)
responded.
Table 1 shows the first-choice treatment
preference for each specialty before and after
equalization for cost and prior authorization.
Methotrexate and mycophenolate mofetil were
the most common agents chosen by both
specialties. However, uveitis specialists and
rheumatologists differed significantly in their
usage both of methotrexate (p\0.009) and
mycophenolate (p\0.015) before equalization
of cost/insurance, with uveitis specialists
choosing mycophenolate nearly as frequently
as methotrexate and rheumatologists choosing
methotrexate almost exclusively. These
differences were not significant after
equalization for cost/prior authorization when
corrected for false discovery rate. Cost/
insurance authorization factors were not found
to be significant for either uveitis specialists
(p = 0.4561) or rheumatologists (p = 0.1714).
There was an increased usage of biologic
agents after adjustment for cost and prior
authorization by uveitis specialists and by
rheumatologists, but the change was only
statistically significant for the rheumatologists
(p\0.05). Local steroid injection was the first
choice of two rheumatologists (intraocular
steroid implant) and five uveitis specialists
(periocular triamcinolone).
Table 2 shows the second-choice treatment
preference for each specialty before and after
equalization for cost and prior authorization.
Biologics were the most common agents
chosen by both specialties, with 51.8% of
rheumatologists and 27.7% of ophthalmologists
preferring this approach (difference between
specialties was not significant after correction for
the false discovery rate). There was an increased
usage of biologics after equalization for cost and
prior authorization by uveitis specialists and by
rheumatologists, but the increase was not
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statistically significant for either. Uveitis
specialists and rheumatologists differed only in
their usage of methotrexate (p\0.001), and this
difference did not persist after equalization of
cost/insurance factors.
Anti-tumor necrosis factor (anti-TNF) agents
and rituximab accounted for the biologic agents
chosen. Specifically, 83.3% of the
rheumatologists who chose a biologic as their
first choice chose an anti-TNF agent, and 93%
chose an anti-TNF agent as their second choice.
No uveitis specialists chose an anti-TNF agent as
their first choice but 90% chose this as their
second choice when selecting a biologic agent.
Table 3 focuses on the differing uses of the
two most popular DMARDs, methotrexate and
mycophenolate, as a first-choice therapy among
rheumatologists and uveitis specialists.
Rheumatologists significantly preferred
methotrexate as a first-choice drug (p\0.001).
Methotrexate was also selected most often by
uveitis specialists, but mycophenolate
represented a significant minority of
responses. This difference persisted after
equalization for cost/prior authorization
(p\0.01).
DISCUSSION
Our data demonstrate that uveitis specialists
and rheumatologists may have different
preferences in the treatment of idiopathic
nodular anterior scleritis. The lack of
evidence-based medicine as well as differences
in specialty paradigms for the treatment of
scleritis lead to a wide spectrum of potential
therapeutic choices within the standard of care.
With the exception of corticosteroids, there are
no Federal Drug Administration
(FDA)-approved agents for the treatment of
scleritis. Hence, all treatment options chosen
by a clinician represent off-label use.
The majority of both types of specialists in
our study chose a systemic immunosuppressive
agent (DMARD) as their first therapeutic choice.
However, there was a strong preference for
methotrexate use by rheumatologists, whereas
it was more likely for uveitis specialists to
choose mycophenolate mofetil. This difference
appeared to persist after equalization for cost
and prior authorization, indicating that
specialty treatment paradigms rather than cost
may be an important determinant in
therapeutic choices. Since the most common
systemic disease associated with scleritis is
rheumatoid arthritis, and methotrexate is a
preferred treatment for this, we believe that
this thinking is reflected in the higher use of
this medication by rheumatologists. While both
agents may be used to treat anterior scleritis
that is inadequately controlled with oral
NSAIDS and prednisone [6–8], this difference
in usage has significant cost implications, as
mycophenolate mofetil is approximately ten
times more costly than methotrexate and has
not been shown to be more efficacious [9, 12].
Table 3 Comparison of preference for methotrexate versus
mycophenolate mofetil as ﬁrst-choice therapy before and after
equalization of cost/authorization among uveitis specialists and
rheumatologists in the treatment of unilateral nodular anterior
scleritis
Uveitis specialists Rheumatologists Level of signiﬁcance
MTX/MM ﬁrst choice (before equalization) 16/10 43/3 p = 0.0013
MTX/MM ﬁrst choice (after equalization) 14/10 34/4 p = 0.0156
MTX methotrexate, MM mycophenolate mofetil
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Neither specialty frequently chose biologic
agents as their first-choice therapy for this
clinical vignette. This appears to be
significantly different than we have
demonstrated in ocular Behc¸et disease, where
both specialties chose biologic agents as the
most common first-choice intervention [10].
However, both the rheumatologists and the
ophthalmologists in the current scleritis study
most commonly chose biologic agents as their
second-choice treatment, without a significant
difference between specialties. It is interesting
to note that the percentage of ophthalmologists
who chose a biologic further increased after cost
equalization, suggesting a greater sensitivity to
treatment cost.
It is important to note that two
rheumatologists and five ophthalmologists
chose a local steroid injection as their
first-choice treatment. The five ophthalmologists
chose periocular steroid injections. Such
injections have been shown to at least
temporarily control symptoms and ocular
inflammation, but there have been several case
reports of extensive scleral melting after local
corticosteroid injection in patients with scleritis,
and this remains an area of controversy
[4, 13, 14]. It is useful to understand that, in
spite of this low risk, uveitis specialists may be
willing to consider this option rather than using
systemic immunosuppression.
A limitation of our study is that we presented
only a single vignette for a patient with anterior
scleritis, whereas there are often other factors
that influence clinical decisions that we did not
address. The low response rate of 8.6% of those
surveyed could influence our results, since
nonresponder bias may be due to survey
recipients being less interested or familiar with
treatment of scleritis. Furthermore, we were
unable to track individuals who did not respond
to our survey, which has the potential to lead to
participation bias. In the United States, a large
percentage of patients with scleritis are
co-managed by rheumatologists and
ophthalmologists who do not specialize in
uveitis, and hence our results cannot be
generalized to other countries.
Our study demonstrates that there may be
significant differences in the therapeutic
choices of specialists in the treatment of
idiopathic scleritis. It is unlikely that direct
comparisons among the therapeutic options for
scleritis will be tested in a randomized
controlled trial. All of the drugs preferred by
both specialties have the potential for
significant side effects and differ greatly in
cost, without proof of superiority or even
equivalence. In the absence of well-controlled
studies, physicians must utilize information
based on training, case series and reports, as
well as personal experience and clinical
judgment. Since these decisions have
meaningful impacts on both healthcare cost
and disease management, further investigation
is warranted.
CONCLUSIONS
Methotrexate was the agent most commonly
chosen by both specialties, but uveitis
specialists were more likely to choose
mycophenolate in the treatment of anterior
scleritis. Cost and the need for prior
authorization were not a significant factor in
these differences, suggesting that subspecialty
training plays a role in these treatment
decisions.
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